Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SLN124

Oligonucleotide (siRNA) · Gene silencing: TMPRSS6 · developed by Silence Therapeutics

Phase 1/2 Most advanced trial
SLN Developer
1 Registered trials

What is SLN124?

SLN124 is an RNA interference therapeutic made of small interfering RNAs conjugated to N-acetylgalactosamine, which binds asialoglycoprotein receptors on hepatocytes. Inside the liver cells, the siRNAs silence TMPRSS6 mRNA, reducing TMPRSS6 protein and allowing hepcidin levels to rise. It is studied in iron-related disorders and polycythemia vera.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Targets
TMPRSS6, asialoglycoprotein receptor (ASGR1) (binding partner it blocks)
Mechanism
Gene silencing: TMPRSS6
Pathways
BMP-SMAD signaling, hepcidin regulation of iron homeostasis
Therapy area
Oncology
Developer
Silence Therapeutics plc (SLN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05499013 Phase 1/2 Polycythemia Vera Active not recruiting SLN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Polycythemia Vera

Other drugs acting on TMPRSS6

More from Silence Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SLN page.

Follow SLN, the company behind SLN124

See SLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SLN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.